Rehmann Capital Advisory Group’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Rehmann Capital Advisory Group’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$44.8K	Hold	5,300	–	–	0.01%	654
2019 Q2	$35.7K	Hold	5,300	–	–	﹤0.01%	955
2019 Q1	$43.5K	Hold	5,300	–	–	0.01%	863
2018 Q4	$84.8K	Hold	5,300	–	–	0.01%	445
2018 Q3	$175K	Hold	5,300	–	–	0.02%	432
2018 Q2	$120K	Hold	5,300	–	–	0.02%	510
2018 Q1	$154K	Hold	5,300	–	–	0.02%	440
2017 Q4	$148K	Hold	5,300	–	–	0.03%	380
2017 Q3	$193K	Buy	+5,300	New	+$164K	0.03%	365

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XSC

X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Rehmann Capital Advisory Group's AVEO Position: Q3 2019 in Review

Rehmann Capital Advisory Group held its AVEO Pharmaceuticals, Inc. (AVEO) position steady in Q3 2019 at 5,300 shares worth $44.8K. The position accounts for 0.01% of the portfolio, ranked #654.

Rehmann Capital Advisory Group first reported a position in AVEO in Q3 2017 and has held it in 9 quarters since. The position peaked at $193K in Q3 2017. 59 funds tracked by Wall St. Rank hold AVEO as of Q3 2019.

Rehmann Capital Advisory Group held 5,300 shares of AVEO Pharmaceuticals, Inc. worth $44.8K as of Q3 2019.
Rehmann Capital Advisory Group left its AVEO Pharmaceuticals, Inc. share count unchanged in Q3 2019.
AVEO Pharmaceuticals, Inc. made up 0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #654 holding.
Rehmann Capital Advisory Group first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2017 and has held it in 9 quarters since.
Rehmann Capital Advisory Group's AVEO Pharmaceuticals, Inc. position peaked at $193K in Q3 2017.
59 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.